OSAM
CORT icon

O'Shaughnessy Asset Management’s Corcept Therapeutics CORT Stock Holding History

O'Shaughnessy Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$301K Buy
+3,459
New +$209K ﹤0.01% 1829
2026
Q1 		– Sell
-6,339
Closed -$221K – 2696
2025
Q4 		$221K Sell
6,339
-1,072
-14% -$84.2K ﹤0.01% 1937
2025
Q3 		$616K Buy
7,411
+129
+2% +$9.34K ﹤0.01% 1376
2025
Q2 		$534K Sell
7,282
-169
-2% -$12.3K ﹤0.01% 1339
2025
Q1 		$851K Sell
7,451
-1,303
-15% -$79.3K 0.01% 1064
2024
Q4 		$441K Buy
8,754
+441
+5% +$23.1K ﹤0.01% 1339
2024
Q3 		$377K Sell
8,313
-93
-1% -$3.31K ﹤0.01% 1352
2024
Q2 		$273K Buy
8,406
+62
+0.7% +$1.7K ﹤0.01% 1408
2024
Q1 		$210K Buy
8,344
+1,808
+28% +$42.7K ﹤0.01% 1484
2023
Q4 		$212K Buy
+6,536
New +$179K ﹤0.01% 1389
2022
Q4 		– Sell
-13,933
Closed -$357K – 1407
2022
Q3 		$357K Buy
13,933
+2,191
+19% +$58.6K 0.01% 866
2022
Q2 		$279K Hold
11,742
– – 0.01% 897
2022
Q1 		$264K Sell
11,742
-19
-0.2% -$404 ﹤0.01% 946
2021
Q4 		$233K Buy
11,761
+973
+9% +$19.7K ﹤0.01% 1000
2021
Q3 		$213K Buy
10,788
+1,679
+18% +$35.1K ﹤0.01% 1011
2021
Q2 		$200K Sell
9,109
-187
-2% -$4.16K ﹤0.01% 1032
2021
Q1 		$221K Buy
9,296
+1
+0% +$27 ﹤0.01% 887
2020
Q4 		$243K Sell
9,295
-19,825
-68% -$418K 0.01% 764
2020
Q3 		$508K Buy
29,120
+19,198
+193% +$306K 0.02% 442
2020
Q2 		$167K Buy
+9,922
New +$139K 0.01% 698
2020
Q1 		– Sell
-90
Closed -$1K – 1385
2019
Q4 		$1K Buy
+90
New +$1.25K ﹤0.01% 1727
2018
Q4 		– Sell
-5,305
Closed -$74K – 934
2018
Q3 		$74K Sell
5,305
-28,617
-84% -$400K ﹤0.01% 680
2018
Q2 		$530K Sell
33,922
-8,995
-21% -$156K 0.01% 344
2018
Q1 		$706K Sell
42,917
-13,355
-24% -$247K 0.02% 297
2017
Q4 		$1.02M Buy
56,272
+7,020
+14% +$127K 0.02% 271
2017
Q3 		$951K Buy
+49,252
New +$734K 0.02% 286

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

O'Shaughnessy Asset Management's CORT Position: Q2 2026 in Review

O'Shaughnessy Asset Management opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 3,459 shares worth $301K. The stake represents ﹤0.01% of the portfolio and ranks #1829 among its holdings. This is a return to the name: O'Shaughnessy Asset Management previously reported a position in CORT as recently as Q4 2025.

O'Shaughnessy Asset Management first reported a position in CORT in Q3 2017 and has held it in 26 quarters since. The position peaked at $1.02M in Q4 2017. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • O'Shaughnessy Asset Management held 3,459 shares of Corcept Therapeutics worth $301K as of Q2 2026.
  • Corcept Therapeutics was a new O'Shaughnessy Asset Management position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of O'Shaughnessy Asset Management's portfolio in Q2 2026, its #1829 holding.
  • O'Shaughnessy Asset Management first reported a position in Corcept Therapeutics in Q3 2017 and has held it in 26 quarters since.
  • O'Shaughnessy Asset Management's Corcept Therapeutics position peaked at $1.02M in Q4 2017.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on O'Shaughnessy Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.